These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 24295065)
1. PEGylated nanomedicines: recent progress and remaining concerns. Vllasaliu D; Fowler R; Stolnik S Expert Opin Drug Deliv; 2014 Jan; 11(1):139-54. PubMed ID: 24295065 [TBL] [Abstract][Full Text] [Related]
2. PEGylated polyester-based nanoncologicals. Conte C; d'Angelo I; Miro A; Ungaro F; Quaglia F Curr Top Med Chem; 2014; 14(9):1097-114. PubMed ID: 24678711 [TBL] [Abstract][Full Text] [Related]
3. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Parveen S; Sahoo SK Clin Pharmacokinet; 2006; 45(10):965-88. PubMed ID: 16984211 [TBL] [Abstract][Full Text] [Related]
4. Silica-Based Nanoparticles for Biomedical Applications: From Nanocarriers to Biomodulators. Yang Y; Zhang M; Song H; Yu C Acc Chem Res; 2020 Aug; 53(8):1545-1556. PubMed ID: 32667182 [TBL] [Abstract][Full Text] [Related]
5. Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns. Zhang X; Wang H; Ma Z; Wu B Expert Opin Drug Metab Toxicol; 2014 Dec; 10(12):1691-702. PubMed ID: 25270687 [TBL] [Abstract][Full Text] [Related]
6. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362 [TBL] [Abstract][Full Text] [Related]
7. Polypeptides as alternatives to PEGylation of therapeutic agents. Chen H; Zhang Q Expert Opin Drug Deliv; 2024; 21(1):1-12. PubMed ID: 38116624 [TBL] [Abstract][Full Text] [Related]
9. PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution. Hussain Z; Khan S; Imran M; Sohail M; Shah SWA; de Matas M Drug Deliv Transl Res; 2019 Jun; 9(3):721-734. PubMed ID: 30895453 [TBL] [Abstract][Full Text] [Related]
10. Nanovesicular carriers as alternative drug delivery systems: ethosomes in focus. Mbah CC; Builders PF; Attama AA Expert Opin Drug Deliv; 2014 Jan; 11(1):45-59. PubMed ID: 24294974 [TBL] [Abstract][Full Text] [Related]
11. Polymer-drug conjugates: origins, progress to date and future directions. Kopeček J Adv Drug Deliv Rev; 2013 Jan; 65(1):49-59. PubMed ID: 23123294 [TBL] [Abstract][Full Text] [Related]
12. Membrane-encapsulated camouflaged nanomedicines in drug delivery. Ghosh S; Girigoswami K; Girigoswami A Nanomedicine (Lond); 2019 Aug; 14(15):2067-2082. PubMed ID: 31355709 [TBL] [Abstract][Full Text] [Related]
13. Ligand-targeted theranostic nanomedicines against cancer. Yao VJ; D'Angelo S; Butler KS; Theron C; Smith TL; Marchiò S; Gelovani JG; Sidman RL; Dobroff AS; Brinker CJ; Bradbury ARM; Arap W; Pasqualini R J Control Release; 2016 Oct; 240():267-286. PubMed ID: 26772878 [TBL] [Abstract][Full Text] [Related]
14. A journey through the history of PEGylated drug delivery nanocarriers. López-Estevez AM; Gref R; Alonso MJ Drug Deliv Transl Res; 2024 Aug; 14(8):2026-2031. PubMed ID: 38796665 [TBL] [Abstract][Full Text] [Related]
15. Nanotechnology Inspired Advanced Engineering Fundamentals for Optimizing Drug Delivery. Kassem AA Curr Drug Targets; 2018; 19(15):1839-1854. PubMed ID: 29412103 [TBL] [Abstract][Full Text] [Related]